On February 22, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) issued the announcement on the approval of holding subsidiaries for drug clinical trials, It is said that the holding subsidiary of the company, Fosun hongchuang (Suzhou) Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Fosun hongchuang”) has received the approval of the State Drug Administration for the development of clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). Fosun hongchuang plans to carry out the phase I clinical trial of the new drug in China (excluding Hong Kong, Macao and Taiwan, the same below).
Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) said that the new drug is a first in class small molecule drug independently developed by the group (i.e. the company and its holding subsidiaries / units, the same below) with new enzyme targets, new action mechanisms and new chemical structure types. It is intended to be used in the treatment of advanced solid tumors and idiopathic pulmonary fibrosis. As of this announcement, the new drug for advanced solid tumors and idiopathic pulmonary fibrosis treatment in the United States in phase I clinical trials, for recurrent, refractory, metastatic breast cancer (including three yin breast cancer) has been certified by the US FDAFastTrackDevelopmentProgram (fast track assessment). The new drug is used for the treatment of advanced solid tumors and is in phase I clinical trial in China.
As of the date of this announcement, no drugs with the same target as the new drug have been listed worldwide.
As of January 2022, the group’s cumulative R & D investment for the new drug at this stage is about RMB 185.42 million (Unaudited).
